Simulations Plus: Buying On Long-Term Silico Drug-Development

Company Overview - Simulations Plus, Inc. (SLP) operates as a pure-play in silico platform focused on model-informed, non-animal drug development [1] - The company integrates software systems with services tailored for clients, enhancing drug development processes [1] Product and Service Offerings - SLP provides a range of software products including GastroPlus, ADMET Predictor, MonolixSuite, DILIsym, and NAFLDsym [1] - The company also offers services in quantitative systems pharmacology (QSP) modeling, clinical pharmacology, training, and medical communications [1]